News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AlphaCore Pharma Granted Orphan Drug Designation for ACP-501 (rhLCAT) by European Medicines Agency



11/2/2012 8:16:18 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced it has received orphan drug designation from the European Medicines Agency (EMA) for ACP-501 for the treatment of familial LCAT deficiency (FLD). This EMA designation follows an earlier FLD orphan drug designation granted by the US Food and Drug Administration.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES